One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Active Surveillance for Low-Risk Cancer-The Waiting Is the Hardest Part.
Accrual to Radiotherapy Trials in the US-Pitfalls and Potential Solutions.
Standardized Definitions for Efficacy End Points for Adjuvant Trials-The Updated STEEP Criteria.
How Can Guidelines Give Clearer Guidance on Prostate Cancer Screening?.
Inpatient Care and Outcomes Among People With Cancer Experiencing Homelessness.
Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer.
Molecular, Socioeconomic, and Clinical Factors Affecting Racial and Ethnic Disparities in Colorectal Cancer Survival.
Chimeric Antigen Receptor T Cells Targeting CD19 and GCC in Metastatic Colorectal Cancer: A Nonrandomized Clinical Trial.
Oral Microbiome and Subsequent Risk of Head and Neck Squamous Cell Cancer.
Complete Response to Locoregional Therapy Plus Immunotherapy for Hepatocellular Carcinoma.
Fracture Risk Prediction Using the Fracture Risk Assessment Tool in Individuals With Cancer.
Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Urothelial Cancer: The FORT-2 Phase 1b Nonrandomized Clinical Trial.
Stereotactic vs Hypofractionated Radiotherapy for Inoperable Stage I Non-Small Cell Lung Cancer: The LUSTRE Phase 3 Randomized Clinical Trial.
Stereotactic Body Radiotherapy for Medically Inoperable Early-Stage Non-Small Cell Lung Cancer.
Heterogeneity of Residual Disease After Neoadjuvant Systemic Therapy in Breast Cancer: A Review.
Radiation-Associated Secondary Cancer in Patients With Breast Cancer Harboring TP53 Germline Variants.
Transperineal vs Transrectal Prostate Biopsy-The PREVENT Randomized Clinical Trial.
Mismatch Repair and Microsatellite Testing for Individuals With Colorectal Cancer.
Meta-Analysis Methods for Neoadjuvant Chemoimmunotherapy for Non-Small Cell Lung Cancer.
Meta-Analysis Methods for Neoadjuvant Chemoimmunotherapy for Non-Small Cell Lung Cancer-Reply.
Ensuring Safety and Consistency in Artificial Intelligence Chatbot Responses.
Ensuring Safety and Consistency in Artificial Intelligence Chatbot Responses-Reply.
